Journal of Neuro-Oncology

, Volume 93, Issue 3, pp 409–412 | Cite as

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report

  • Roy Torcuator
  • Richard Zuniga
  • Randa Loutfi
  • Tom Mikkelsen
Case report


Diffuse brainstem glioma carries a dismal prognosis. The current cornerstone of treatment is radiation therapy. Chemotherapy appears to be ineffective and the role of this treatment in the recurrent or progressive setting is not known. Bevacizumab and irinotecan have been reported to have shown radiographic response and improvement in progression-free survival among patients with malignant supratentorial gliomas. In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan.


Brainstem Glioma Diffuse chemotherapy Bevacizumab Irinotecan 


  1. 1.
    Packer RJ (1999) Brain tumors in children. Arch Neurol 56(4):421–425. doi: 10.1001/archneur.56.4.421 PubMedCrossRefGoogle Scholar
  2. 2.
    Freeman CR, Farmer JP (1998) Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40(2):265–271. doi: 10.1016/S0360-3016(97)00572-5 PubMedGoogle Scholar
  3. 3.
    Rubin G, Michowitz S, Horev G, Herscovici Z, Cohen IJ, Shuper A, Rappaport ZH (1998) Pediatric brain stem gliomas: an update. Childs Nerv Syst 14(4–5):167–173. doi: 10.1007/s003810050205 PubMedCrossRefGoogle Scholar
  4. 4.
    Guillamo JS, Monjour A, Taillandier L, Devaux B, Varlet P, Haie-Meder C, Defer GL, Maison P, Mazeron JJ, Cornu P, Delattre JY, Association des Neuro-Oncoloques d’Expression Francoise (ANOCEF) (2001) Brainstem gliomas in adults: prognostic factors and classification. Brain 124(Pt 12):2528–2539. doi: 10.1093/brain/124.12.2528 PubMedCrossRefGoogle Scholar
  5. 5.
    Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, Giombini S, Poggi G, Pecori E, Pignoli E, Casanova M, Ferrari A, Meazza C, Luksch R, Terenziam M, Cefalo G, Podda M, Polastri D, Clerici CA, Fossati-Bellani F, Gondola L (2008) Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 87(3):355–361. doi: 10.1007/s11060-008-9525-5 PubMedCrossRefGoogle Scholar
  6. 6.
    Landolfi JC, Thaler HT, DeAngelis LM (1998) Adult brainstem gliomas. Neurology 51(4):1136–1139PubMedGoogle Scholar
  7. 7.
    Selvapandian S, Rajshekhar V, Chandy MJ (1999) Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 141(7):721–726. doi: 10.1007/s007010050367 (discussion 726–727)CrossRefGoogle Scholar
  8. 8.
    Epstein F, Constantini S (1996) Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 24(1):24–34. doi: 10.1159/000121011 PubMedCrossRefGoogle Scholar
  9. 9.
    Schild SE, Stafford SL, Brown PD, Wood CP, Scheithauer BW, Schombert PJ, Wong WW, Lyons MK, Shaw EG (1998) The results of radiotherapy for brainstem tumors. J Neurooncol 40(2):171–177. doi: 10.1023/A:1006193306286 PubMedCrossRefGoogle Scholar
  10. 10.
    Freeman CR, Perilongo G (1999) Chemotherapy for brain stem gliomas. Childs Nerv Syst 15(10):545–553. doi: 10.1007/s003810050542 PubMedCrossRefGoogle Scholar
  11. 11.
    Shuper A, Kornreich L, Loven D, Michowitz S, Schwartz M, Cohen IJ (1998) Diffuse brain stem gliomas. Are we improving outcome? Childs Nerv Syst 14(10):578–581. doi: 10.1007/s003810050275 PubMedCrossRefGoogle Scholar
  12. 12.
    Bouffet E, Khelfaoui F, Philip I, Biron P, Brunet-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39(4):376–379. doi: 10.1007/s002800050586 PubMedCrossRefGoogle Scholar
  13. 13.
    Allen JC, Siffert J (1996) Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 24(2):98–102. doi: 10.1159/000121024 PubMedCrossRefGoogle Scholar
  14. 14.
    Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D, Kuehl J (2002) Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87(9):945–949. doi: 10.1038/sj.bjc.6600552 PubMedCrossRefGoogle Scholar
  15. 15.
    Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi: 10.1158/1078-0432.CCR-06-2309 PubMedCrossRefGoogle Scholar
  16. 16.
    Vredenburgh JJ, Desjardins A, Herndon JEII, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729. doi: 10.1200/JCO.2007.12.2440 PubMedCrossRefGoogle Scholar
  17. 17.
    Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, hiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s (abstr 2010b)Google Scholar
  18. 18.
    Gururangan S, Chi S, Onar A, Packer R, Young Poussaint T, Gilbertson R, Friedman H, Kun L, Boyett J (2008) Phase II study of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma—a Pediatric Brain Consortium Study (PBTC-022). Neuro Oncol 5:833 (abstract MA-63)Google Scholar
  19. 19.
    Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197–206. doi: 10.1634/theoncologist.9-2-197 PubMedCrossRefGoogle Scholar
  20. 20.
    Lu C, Shervington A (2008) Chemoresistance in gliomas. Mol Cell Biochem 312:71–80. doi: 10.1007/s11010-008-9722-8 PubMedCrossRefGoogle Scholar
  21. 21.
    Reddy A, Mapstone T (2000) Brain stem tumors. In: Bernstein M, Berger MS (eds) Neuro-oncology the essentials. Thieme Medical Publishers, Inc, New York, pp 352–386Google Scholar
  22. 22.
    Packer RJ, Prados M, Phillips P, Nicholson HS, Bovett JM, Goldwein J, Rorke LB, Needle MN, Sutton L, Zimmerman RA, Fitz CR, Vezina LG, Etcubanas E, Wallenberg JC, Reaman G, Wara W (1996) Treatment of children with newly diagnosed brainstem gliomas with intravenous recombinant beta-inteferon and hyperfractionated radiation therapy: a Childrens Cancer Group phase I/II study. Cancer 77:2150–2156. doi:10.1002/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>3.0.CO;2-TPubMedCrossRefGoogle Scholar
  23. 23.
    Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goulmnerova L, Billett AL, Kieran M, Tarbell NJ (2003) A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 55(5):1182–1185. doi: 10.1016/S0360-3016(02)04391-2 PubMedGoogle Scholar
  24. 24.
    Findlay JL, Zacharoulis S (2005) The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical- and futuristic-perspective. J Neurooncol 75:253–266. doi: 10.1007/s11060-005-6747-7 CrossRefGoogle Scholar
  25. 25.
    Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumors. Nat Rev Neurosci 8(8):610–622. doi: 10.1038/nrn2175 PubMedCrossRefGoogle Scholar
  26. 26.
    Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19(4(Suppl 3)):7–16 (Williston Park)PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Roy Torcuator
    • 1
    • 2
  • Richard Zuniga
    • 1
  • Randa Loutfi
    • 3
  • Tom Mikkelsen
    • 1
    • 2
    • 4
  1. 1.Department of NeurosurgeryHenry Ford Health System, Hermelin Brain Tumor CenterDetroitUSA
  2. 2.Henry Ford Health SystemHermelin Brain Tumor CenterDetroitUSA
  3. 3.Department of Medical OncologyHenry Ford Health System, Hermelin Brain Tumor CenterDetroitUSA
  4. 4.Department of NeurologyHenry Ford Health System, Hermelin Brain Tumor CenterDetroitUSA

Personalised recommendations